Excited to attend and speak at FOCIS 20225 next week! @Focis_FCE @focisimmunology #FOCIS #FOCIS2025 focisnet.org/meetings/focis-…

This cover art was based on real TEM images of mitochondria of exhausted CAR-T cells reinvigorated by IL-10. Kudos to Yiling Li, a PhD student of my former postdoc, Prof. Yugang Guo @YugangGUO2 @ZJU_China

Further mechanistic studies show that Fc–IL-4 signals through both signal transducer and activator of transcription 6 (STAT6) and mammalian target of rapamycin (mTOR) pathways to enhance glycolysis, survival, and effector function of CD8+ TTEcells. (9/11)

We next show Fc–IL-4 augments the glycolytic metabolism and increases the NAD concentration of CD8+ TTE cells; LDHA is significantly upregulated by Fc–IL-4 and plays an indispensable role for Fc–IL-4 to improve the metabolism and effector function of CD8+ TTE cells.(8/11)

We further found that Fc–IL-4 specifically enriches the terminally exhausted CD8+ T (CD8+ TTE) in tumor and promotes their effector function. Interestingly, the enrichment of CD8+ TTE induced by Fc–IL-4 was mainly due to alleviated cell apoptosis.(7/11)

We first show that Fc–IL-4 combined with type 1-centric ACT and ICB therapies efficiently eliminates solid tumors in multiple syngeneic and xenograft models. Strikingly, all cured mice resisted the secondary rechallenge suggesting induction of long-term memory.(6/11)

In the second @nature paper, a long-term clinical study, led by @RongFan8 @GruppSteve @carlhjune @MelenhorstLab and us @Tang_Lab_EPFL, reveals that type-2 functionality in CAR-T infusion products favours 8-year relapse-free leukaemia remission in patients! (2/11)

Thrilled to share our back-to-back two Nature @Nature papers on the unexpected role of type 2 immunity against cancer. We found that interleukin 4 (Fc–IL-4), a type 2 cytokine, reinvigorates exhausted T cells to potentiate anticancer immunotherapy w/ @YugangGUO2 @RongFan8(1/11)

Heading to @AACR 2024 in SD! For the first time, Leman Biotech will publicly present the IIT results on investigating Meta 10-19 CAR-T cell therapy for r/r CD19 B cell malignancies in an oral presentation (3:50-4:05 pm, April 8th, Minisymposium Late-Breaking Research Session)!

In addition, IL-10 secretion also promoted T cell stemness and memory T cells, leading to durable antitumor responses and rapid tumor clearance upon rechallenge. (8/)